ClinicalTrials.gg
CompletedNCT06305416Updated Sep 25, 2026

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

A Phase 3 interventional study of Ranibizumab 10mg/ml Injection and Lucentis in Diabetic Macular Edema, Diabetic Retinopathy and Macular Edema, sponsored by Incepta Pharmaceuticals Ltd. Completed at 1 site in Bangladesh. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Incepta Pharmaceuticals Ltd · Phase 3, Interventional, and Treatment

Updated Sep 25, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing ranibizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Ranibizumab · Diabetic Retinopathy.

Enrollment
15th of 34
70 · median 57
Started
2024
the only one that year
Phase 3
9 of 34
1 open now
Registered
32nd of 34
by date
Lead sponsor
1 of 34
Incepta Pharmaceuticals Ltd

Among the 34 studies testing ranibizumab in Diabetic Retinopathy, this one is the 15th largest by enrollment, is the only one that started in 2024, is one of 9 in phase 3, and was the 32nd registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 34 studies testing ranibizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing ranibizumab in Diabetic Retinopathy, or all of them as a file.
02

Study summary

Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma constituents into the surrounding retina and consequently retinal edema. Thickening of the basement membrane and reduction in the number of pericytes are believed to lead to increased permeability and incompetence of the retinal vasculature. This compromise of the blood-retinal barrier leads to the leakage of plasma constituents into the surrounding retina with subsequent retinal edema. Hypoxia produced by this mechanism can also stimulate the production of vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) increases retinal vascular permeability, causes breakdown of the blood-retina barrier and results in retinal edema.

Diabetic macular edema (DME) is the most common cause of visual reduction in patients with Diabetes Mellitus. The prevalence of DME globally is around 6.8 %. Diabetic Retinopathy (DR) is the most common microvascular complication of diabetes and the leading cause of blindness worldwide. DME is a complication of diabetic retinopathy that affects the macula, which is located at the center of the retina and responsible for central vision. Bangladesh is the 10th country in the world for the number of adults living with diabetes with some 7.1 million (5.3-12.0). In Bangladesh, it is therefore expected that diabetic secondary complications, like DR, will increase along with the rising trend of diabetes mellitus.

The use of therapeutic monoclonal antibodies has revolutionized in the treatment of many diseases. In recent years, millions of patients have been successfully treated with these biological agents. Ranibizumab is one such therapeutic monoclonal antibody for intraocular use. Ranibizumab is a humanized, recombinant, immunoglobulin G1 monoclonal antibody fragment against vascular endothelial growth factor A (VEGF-A) and thus prevents choroidal neovascularization. The small size of ranibizumab allows for enhanced diffusion into the retina and choroid.

Read the detailed description

This is a randomized, double-blind, parallel study that will be conducted in patients with Diabetic Macular Edema (DME) to assess efficacy and safety between test and reference products. Total 70 subjects with DME are planned to be randomized into this study.

Enrolled subjects will receive total 3 doses of 0.5 mg Intravitreal injection of either test or reference product once every 4 Weeks (Day 0, Week 4±3 days and Week 8±3 days). All subjects will have their first injection of ranibizumab on Day 0 and undergo a safety visit 48hrs after the first injection. At subsequent visits, the subject will have a safety follow up prior to each intravitreal injection. Also the subject will have a safety follow up visit 48hrs after second and third injection. The final visit or end of study visit will be on Week 12±3 days for efficacy and safety evaluation.

03

Conditions studied

  • Diabetic Macular Edema
  • Diabetic Retinopathy
  • Macular Edema
  • Macular Degeneration
  • Retinal Disease
  • Retinal Degeneration

Keywords

  • Ranibizumab
  • Efficacy
  • Diabetes
  • Retina
  • Edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages Eligible for Study: ≥ 18 Years
  2. Ability to provide written and comply with study assessments for the full duration of the study
  3. Diagnosis of diabetes mellitus (type 1 or 2). Any one of the following will be considered to be sufficient evidence that diabetes is present: Laboratory reports that prove DM of patient or current regular use of insulin for treatment of diabetes or current regular use of oral anti-hyperglycemic agent for the treatment of diabetes.
  4. Clinical evidence of retinal thickening due to macular edema involving the center of the macula (can be associated with diabetic retinopathy)
  5. Central diabetic macular edema present on clinical examination and OCT testing with central 1mm sub field thickness greater than 300 microns as measured on -OCT
  6. Visual acuity score greater than or equal to 19 letters (20/400) and less than or equal to 73 letters (20/40) by the ETDRS/ Snellen chart visual acuity protocol
  7. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography
  8. Willingness and ability to undertake all scheduled visits and assessments

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with any Intravitreal drug, Bevacizumab, verteporfin or photodynamic therapy (except for extra foveal laser photocoagulation) in the study eye within past 3 months before study entry
  2. Laser photocoagulation in the study eye within 1 month before study entry
  3. Participation in another ocular investigation or trial simultaneously
  4. Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate .
  5. Blood pressure > 160/100 mmHg (systolic above 160 or diastolic above 100) and Random Blood Sugar (RBS) ≥ 12 mmol/L and/ or ≥ 7.5%
  6. Evidence of vitreoretinal interface abnormality and optic nerve disease after ocular exam or OCT that may be contributing to the macular edema
  7. Any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the study period or that could contribute to a loss of best corrected visual acuity over the study period (e.g. cataract that might decrease the vision by 3 or more lines, uncontrolled glaucoma, uveitis, previous corneal transplant etc.). The decision regarding exclusion is to be based on the opinion of the investigator.
  8. An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of sub retinal fibrosis or geographic atrophy).
  9. Presence of suspected ocular or periocular infections, another ocular condition that may affect the visual acuity or macular edema during the course of the study (uveitis, Irvine-Gas)
  10. Vitreous hemorrhage preventing visualization of retina
  11. History of vitreous surgery, cataract surgery, YAG capsulotomy in the study eye within last 3 months of enrolment
  12. Visual acuity \<20/400 in the fellow eye
  13. Known to Ranibizumab or any of the components of study medication
  14. History of cerebral vascular accident or myocardial infarction within past 3 months.
  15. Employees of sites, individuals directly involved with the conduct of the study or immediate family members thereof, prisoners, and persons who are legally institutionalized.
  16. Current use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/ hydroxychloroquine, tamoxifen, phenothiazine, vigabatrin and ethambutol, and such medications will not be allowed during the study period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Ranibizumab 10mg/ml Injection (Proposed Ranibizumab Biosimilar)

    Test Group of 35 adult patient with DME will get Ranibizumab (Proposed Ranibizumab Biosimilar)

    Drug: Ranibizumab 10mg/ml Injection

  • Active comparator
    Lucentis (Ranibizumab)

    Comparator Group of 35 adult patient with DME will get Lucentis

    Drug: Lucentis

Interventions

  • DrugRanibizumab 10mg/ml Injection

    Drug page: Ranibizumab

    Ranibizumab 10mg/ml Injection (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks

    Also known as: Test Product

  • Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks

    Also known as: Reference Product

06

What researchers measure

Primary outcomes

  1. Changes in Best Corrected Visual Acuity (BCVA) from Baseline

    To determine the changes in the BCVA was assessed using ETDRS charts or Snellen charts from baseline to Week 12

    Time frame: Baseline and Week 12

  2. Changes in Central Subfield Thickness (CST) from Baseline

    To determine the changes in central 1mm subfield thickness as measured by OCT and FA from baseline to week 12

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Proportion of patients who lost fewer than 15 letters (approximately 3 lines) from baseline visual acuity

    The VA will be assessed using ETDRS charts or Snellen charts.

    Time frame: Baseline and Week 12

  2. Proportion of patients who gained ≥15 letters (approximately 3 lines) from baseline visual acuity

    The VA will be assessed using ETDRS charts or Snellen charts.

    Time frame: Baseline and Week 12

  3. Evaluation and comparison of safety between reference vs. test drug.

    Incidence of drug related adverse events as assessed by clinical and ophthalmic examination, vitals and laboratory parameters in both treatment arms

    Time frame: Baseline and upto Week 12

07

Study locations

1 site
  • Bangladesh Eye Hospital & Institute
    Dhaka, 1209, Bangladesh
08

References and documents

Individual participant data

Plan to share: Yes — By publication in the journal

Supporting information: Study protocol, Clinical study report

Time frame: After completion of study

Access criteria: Journal

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Mar 2026, 23 months.

Of 21 phase 3 interventional studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 41. This study's 23 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Oct 2025 → Mar 2026 and completion Dec 2025 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 12, 2024
StartActual
Mar 30, 2024
Primary completionActual
Mar 10, 2026was Oct 2025
CompletionActual
May 17, 2026was Dec 2025
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 25, 2026
Primary completion
Oct 2025→Mar 10, 2026 (actual)
Sep 25, 2026
Study completion
Dec 2025→May 17, 2026 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Completed
    Primary completion Oct 2025→Mar 10, 2026 (now actual)
    Study completion Dec 2025→May 17, 2026 (now actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06305416
Lead sponsor
Incepta Pharmaceuticals Ltd
Collaborators
Institute for Developing Science and Health Initiatives, Bangladesh
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Mar 30, 2024
Primary completion
Mar 10, 2026
Completion
May 17, 2026
Last update
Sep 25, 2026

Study contacts

Dr. Niaz Abdur Rahman
principal investigator · Managing Director, Bangladesh Eye Hospital & Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion